Falkai, Peter
Schmitt, Andrea
Rosenbeiger, Christian P.
Maurus, Isabel http://orcid.org/0000-0002-6208-5180
Hattenkofer, Lisa
Hasan, Alkomiet
Malchow, Berend
Heim-Ohmayer, Pascale
Halle, Martin
Heitkamp, Melanie
Funding for this research was provided by:
dfg (Klinische Forschergruppe (KFO) 241, PsyCourse (FA241/16–1))
bmbf (01EE1407E, 01EE1407E, 01EE1407E)
Ludwig-Maximilians-Universität München
Article History
Received: 16 June 2021
Accepted: 24 November 2021
First Online: 6 December 2021
Declarations
:
: C.P. Rosenbeiger, I. Maurus, B. Malchow, L. Hattenkofer, P. Heim-Ohmayer, M. Halle, and M. Heitkamp report no conflicts of interest. A. Hasan has been invited to scientific meetings by Lundbeck, Janssen, and Pfizer, and he received paid speakerships from Janssen, Otsuka, and Lundbeck. He was member of Roche, Otsuka, Lundbeck, and Janssen advisory boards. A. Schmitt was an honorary speaker for TAD Pharma and Roche and a member of Roche advisory boards. P. Falkai has been an honorary speaker for AstraZeneca, Bristol Myers Squibb, Lilly, Essex, GE Healthcare, GlaxoSmithKline, Janssen Cilag, Lundbeck, Otsuka, Pfizer, Servier, and Takeda and has been a member of the advisory boards of Janssen-Cilag, AstraZeneca, Lilly, and Lundbeck.